Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAKWATER first-line encorafenib + cetuximab with or without chemotherapy in BRAF V600E metastatic colorectal cancer
NL-OMON54332Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of encorafenib and cetuximab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (7 arms), sponsored by Pfizer. Started Mar 2022; status: recruiting.
02
Drugs
encorafenibcetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON54332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54332.